Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;13(6):2820-2834.
doi: 10.1002/jcsm.13089. Epub 2022 Sep 29.

Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis

Affiliations
Review

Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis

Kevin R Keene et al. J Cachexia Sarcopenia Muscle. 2022 Dec.

Abstract

Ophthalmoparesis and ptosis can be caused by a wide range of rare or more prevalent diseases, several of which can be successfully treated. In this review, we provide clues to aid in the diagnosis of these diseases, based on the clinical symptoms, the involvement pattern and imaging features of extra-ocular muscles (EOM). Dysfunction of EOM including the levator palpebrae can be due to muscle weakness, anatomical restrictions or pathology affecting the innervation. A comprehensive literature review was performed to find clinical and imaging clues for the diagnosis and follow-up of ptosis and ophthalmoparesis. We used five patterns as a framework for differential diagnostic reasoning and for pattern recognition in symptomatology, EOM involvement and imaging results of individual patients. The five patterns were characterized by the presence of combination of ptosis, ophthalmoparesis, diplopia, pain, proptosis, nystagmus, extra-orbital symptoms, symmetry or fluctuations in symptoms. Each pattern was linked to anatomical locations and either hereditary or acquired diseases. Hereditary muscle diseases often lead to ophthalmoparesis without diplopia as a predominant feature, while in acquired eye muscle diseases ophthalmoparesis is often asymmetrical and can be accompanied by proptosis and pain. Fluctuation is a hallmark of an acquired synaptic disease like myasthenia gravis. Nystagmus is indicative of a central nervous system lesion. Second, specific EOM involvement patterns can also provide valuable diagnostic clues. In hereditary muscle diseases like chronic progressive external ophthalmoplegia (CPEO) and oculo-pharyngeal muscular dystrophy (OPMD) the superior rectus is often involved. In neuropathic disease, the pattern of involvement of the EOM can be linked to specific cranial nerves. In myasthenia gravis this pattern is variable within patients over time. Lastly, orbital imaging can aid in the diagnosis. Fat replacement of the EOM is commonly observed in hereditary myopathic diseases, such as CPEO. In contrast, inflammation and volume increases are often observed in acquired muscle diseases such as Graves' orbitopathy. In diseases with ophthalmoparesis and ptosis specific patterns of clinical symptoms, the EOM involvement pattern and orbital imaging provide valuable information for diagnosis and could prove valuable in the follow-up of disease progression and the understanding of disease pathophysiology.

Keywords: Extra-ocular muscles; Imaging; Involvement pattern; Neuromuscular disease; Ophthalmoparesis; Ptosis.

PubMed Disclaimer

Conflict of interest statement

K. R. Keene reports involvement in myasthenia gravis research sponsored by Argenx, Alexion Pharmaceuticals and the CHDR, with all reimbursements received by Leiden University Medical Center and research support from Philips Healthcare. H. E. Kan reports research support from Philips Healthcare, trial support from ImagingDMD; no personal fees are received, and all revenues go to the LUMC S. van Meeren reports no disclosures. B. M. Verbist reports no disclosures. M. R. Tannemaat reports trial support from Argen‐X and Alexion. J. W. M. Beenakker reports research support from Philips Healthcare. J. J. G. M. V. has been involved in MG research sponsored by the Princes Beatrix Fonds, Health Holland and consultancies for Argen‐X, Alexion, and NMD Pharma. Reimbursements were received by the LUMC. He is a co‐inventor on patent applications based on MuSK‐related research. The LUMC receives royalties for MuSK antibody assays.

Figures

Figure 1
Figure 1
Five patterns characterized by the presence of combination of ptosis, ophthalmoparesis, diplopia, pain, proptosis, nystagmus, extra‐orbital symptoms, symmetry or fluctuations in symptoms. Each pattern was linked to anatomical locations and either hereditary or acquired diseases, as a starting point for clinical evaluation rather than providing a stringent, mutually exclusive classification.
Figure 2
Figure 2
Magnetic resonance imaging scans of the orbit. Chemical shift‐based water–fat separation (using the Dixon technique) was used and the water image is shown; on top the transverse image and on bottom the coronal image. Volume decrease, indicative of atrophy, of the extra‐ocular muscle (EOM) is clearly demonstrated in chronic progressive external ophthalmoplegia and enlargement of the EOM in Graves' orbitopathy.
Figure 3
Figure 3
Magnetic resonance imaging scans of the orbit. Chemical shift‐based water–fat separation (using the Dixon technique) was used and the transverse water image (first), transverse fat image (second), the coronal water image (third) and the coronal fat image (fourth) are shown. This MRI scan demonstrates fat replacement of the extra‐ocular muscle in a patient with oculo‐pharyngeal muscular dystrophy. The fat replacement is predominantly observed in the lateral rectus muscles (red arrows).
Figure 4
Figure 4
Involvement pattern of the six extra‐ocular muscles and the levator palpebrae superioris muscle for brain diseases, nerve diseases, muscle diseases and synaptic disease split into either acquired or hereditary. An example of the right eye is shown.

Similar articles

Cited by

References

    1. Heidary G, Engle EC, Hunter DG. Congenital fibrosis of the extraocular muscles. Semin Ophthalmol 2008;23:3–8. - PubMed
    1. Al Othman B, Raabe J, Kini A, Lee AG. Update: the Miller–Fisher variants of Guillain–Barré syndrome. Curr Opin Ophthalmol 2019;30:462–466. - PubMed
    1. Filho ARG, Faccenda PG, Estacia CT, Correa BS, Curi I. Tolosa–Hunt syndrome. Rev Bras Oftalmol 2018;77:289–291.
    1. Mansukhani SA, Bothun ED, Diehl NN, Mohney BG. Incidence and ocular features of pediatric myasthenias. Am J Ophthalmol 2019;200:242–249. - PMC - PubMed
    1. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers 2019;5:30. - PubMed

MeSH terms